Archives of Clinical Infectious Diseases

Published by: Kowsar

Prevalence and Risk Factors for Occult Hepatitis B and HIV Infections Among HCV Infected Intravenous Drug Users, Tehran, Iran

Behnoosh Eshraghi Mosa Abadi 1 , 2 , Tahmineh Kandelouei 1 , 2 , Gita Eslami 3 , Maryam Asli 2 and Maryam Vaezjalali 1 , 3 , *
Authors Information
1 Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Department of Microbiology, Faculty of Biological Sciences, Shahid Beheshti University, Tehran, Iran
3 Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Article information
  • Archives of Clinical Infectious Diseases: December 2018, 13 (6); e67968
  • Published Online: September 3, 2018
  • Article Type: Research Article
  • Received: January 30, 2017
  • Revised: February 20, 2018
  • Accepted: April 10, 2018
  • DOI: 10.5812/archcid.3075

To Cite: Eshraghi Mosa Abadi B, Kandelouei T, Eslami G, Asli M, Vaezjalali M. Prevalence and Risk Factors for Occult Hepatitis B and HIV Infections Among HCV Infected Intravenous Drug Users, Tehran, Iran, Arch Clin Infect Dis. 2018 ; 13(6):e67968. doi: 10.5812/archcid.3075.

Abstract
Copyright © 2018, Archives of Clinical Infectious Diseases. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
References
  • 1. Hassannejad R, Kassaian N, Ataei B, Adibi P. High risky behaviors among intravenous drug users in Isfahan, Iran: A study for hepatitis C harm reduction programs. Int J Prev Med. 2012;3(Suppl 1):S73-8. [PubMed: 22826773]. [PubMed Central: PMC3399296].
  • 2. Samimi-Rad K, Nasiri Toosi M, Masoudi-Nejad A, Najafi A, Rahimnia R, Asgari F, et al. Molecular epidemiology of hepatitis C virus among injection drug users in Iran: a slight change in prevalence of HCV genotypes over time. Arch Virol. 2012;157(10):1959-65. doi: 10.1007/s00705-012-1369-9. [PubMed: 22695769].
  • 3. Haussig JM, Nielsen S, Gassowski M, Bremer V, Marcus U, Wenz B, et al. A large proportion of people who inject drugs are susceptible to hepatitis B: Results from a bio-behavioural study in eight German cities. Int J Infect Dis. 2018;66:5-13. doi: 10.1016/j.ijid.2017.10.008. [PubMed: 29097248].
  • 4. Makvandi M. Update on occult hepatitis B virus infection. World J Gastroenterol. 2016;22(39):8720-34. doi: 10.3748/wjg.v22.i39.8720. [PubMed: 27818588]. [PubMed Central: PMC5075547].
  • 5. Said ZN. An overview of occult hepatitis B virus infection. World J Gastroenterol. 2011;17(15):1927-38. doi: 10.3748/wjg.v17.i15.1927. [PubMed: 21528070]. [PubMed Central: PMC3082745].
  • 6. Branco F, Mattos AA, Coral GP, Vanderborght B, Santos DE, Franca P, et al. Occult hepatitis B virus infection in patients with chronic liver disease due to hepatitis C virus and hepatocellular carcinoma in Brazil. Arq Gastroenterol. 2007;44(1):58-63. [PubMed: 17639185].
  • 7. Daw MA, Shabash A, El-Bouzedi A, Dau AA. Association with the Libyan Study Group of Hepatitis and HIV. Seroprevalence of HBV, HCV & HIV co-infection and risk factors analysis in Tripoli-Libya. PLoS One. 2014;9(6). e98793. doi: 10.1371/journal.pone.0098793. [PubMed: 24936655]. [PubMed Central: PMC4060988].
  • 8. Ramezani A, Banifazl M, Aghakhani A. Occult hepatitis B infection in chronic hemodialysis patients: Comparison of results and concepts: Occult HBV in chronic hemodialysis patients. Hepat Mon. 2011;11(2):128-9. [PubMed: 22087131]. [PubMed Central: PMC3206674].
  • 9. Okocha EC, Oguejiofor OC, Odenigbo CU, Okonkwo UC, Asomugha L. Prevalence of hepatitis B surface antigen seropositivity among HIV-infected and non-infected individuals in Nnewi, Nigeria. Niger Med J. 2012;53(4):249-53. doi: 10.4103/0300-1652.107605. [PubMed: 23661888]. [PubMed Central: PMC3640249].
  • 10. Askari A, Hakimi H, Nasiri Ahmadabadi B, Hassanshahi G, Kazemi Arababadi M. Prevalence of hepatitis B co-infection among HIV positive patients: narrative review article. Iran J Public Health. 2014;43(6):705-12. [PubMed: 26110141]. [PubMed Central: PMC4475589].
  • 11. Jahanbakhsh A, Farzinepoor Z, Mansouri F, Vaziri S, Afsharian M. Prevalence of occult hepatitis B in HIV positive patients (adolescents and adults) in Kermanshah-Iran. Int J Pediat. 2017;5(9):5797-803.
  • 12. Bautista-Amorocho H, Castellanos-Dominguez YZ, Rodriguez-Villamizar LA, Velandia-Cruz SA, Becerra-Pena JA, Farfan-Garcia AE. Epidemiology, risk factors and genotypes of HBV in HIV-infected patients in the northeast region of Colombia: high prevalence of occult hepatitis B and F3 subgenotype dominance. PLoS One. 2014;9(12). e114272. doi: 10.1371/journal.pone.0114272. [PubMed: 25462190]. [PubMed Central: PMC4252145].
  • 13. Asli M, Kandelouei T, Rahimyan K, Davoodbeglou F, Vaezjalali M. Characterization of Occult Hepatitis B Infection Among Injecting Drug Users in Tehran, Iran. Hepat Mon. 2016;16(3). e34763. doi: 10.5812/hepatmon.34763. [PubMed: 27226802]. [PubMed Central: PMC4875578].
  • 14. Amin-Esmaeili M, Rahimi-Movaghar A, Razaghi EM, Baghestani AR, Jafari S. Factors correlated with hepatitis C and B virus infections among injecting drug users in Tehran, IR Iran. Hepat Mon. 2012;12(1):23-31. doi: 10.5812/kowsar.1735143X.806. [PubMed: 22451840]. [PubMed Central: PMC3298872].
  • 15. Sarkari B, Eilami O, Khosravani A, Sharifi A, Tabatabaee M, Fararouei M. High prevalence of hepatitis C infection among high risk groups in Kohgiloyeh and Boyerahmad Province, Southwest Iran. Arch Iran Med. 2012;15(5):271-4. [PubMed: 22519374].
  • 16. Malekinejad M, Navadeh S, Lotfizadeh A, Rahimi-Movaghar A, Amin-Esmaeili M, Noroozi A. High hepatitis C virus prevalence among drug users in Iran: systematic review and meta-analysis of epidemiological evidence (2001-2012). Int J Infect Dis. 2015;40:116-30. doi: 10.1016/j.ijid.2015.09.022. [PubMed: 26460088].
  • 17. Bagheri Amiri F, Mostafavi E, Mirzazadeh A. HIV, HBV and HCV coinfection prevalence in Iran: A systematic review and meta-analysis. PLoS One. 2016;11(3). e0151946. doi: 10.1371/journal.pone.0151946. [PubMed: 27031352]. [PubMed Central: PMC4816272].
  • 18. Merat S, Rezvan H, Nouraie M, Abolghasemi H, Jamali R, Amini-Kafiabad S, et al. Seroprevalence and risk factors of hepatitis A virus infection in Iran: a population based study. Arch Iran Med. 2010;13(2):99-104. [PubMed: 20187662].
  • 19. Lin CL, Liu CJ, Chen PJ, Lai MY, Chen DS, Kao JH. High prevalence of occult hepatitis B virus infection in Taiwanese intravenous drug users. J Med Virol. 2007;79(11):1674-8. doi: 10.1002/jmv.20985. [PubMed: 17854041].
  • 20. Zhou YH, Yao ZH, Liu FL, Li H, Jiang L, Zhu JW, et al. High prevalence of HIV, HCV, HBV and co-infection and associated risk factors among injecting drug users in Yunnan province, China. PLoS One. 2012;7(8). e42937. doi: 10.1371/journal.pone.0042937. [PubMed: 22916185]. [PubMed Central: PMC3420897].
  • 21. Imani R, Karimi A, Rouzbahani R, Rouzbahani A. Seroprevalence of HBV, HCV and HIV infection among intravenous drug users in Shahr-e-Kord, Islamic Republic of Iran. E Mediterr Health J. 2008;14(5):1136-41.
  • 22. Nikkhooy A, Nikkhooy M, Saadati N. Determination of relative frequency of HBS Ag, HCV and HIV antibodies serum markers among admitted intravenous drug users in infectious disease ward of Razi Hospital in Ahvaz, 2004 - 2005. J Health Res. 2012;1(1):26-33.
  • 23. Ataei B, Tayeri K, Kassaian N, Farajzadegan Z, Babak A. Hepatitis B and C among patients infected with human immunodeficiency virus in Isfahan, Iran: seroprevalence and associated factors. Hepat Mon. 2010;10(3):188-92. [PubMed: 22308138]. [PubMed Central: PMC3269083].
  • 24. Sofian M, Aghakhani A, Banifazl M, Azadmanesh K, Farazi AA, McFarland W, et al. Viral hepatitis and HIV infection among injection drug users in a central Iranian City. J Addict Med. 2012;6(4):292-6. doi: 10.1097/ADM.0b013e3182659928. [PubMed: 22895463].
  • 25. Rahimi-Movaghar A, Razaghi EM, Sahimi-Izadian E, Amin-Esmaeili M. HIV, hepatitis C virus, and hepatitis B virus co-infections among injecting drug users in Tehran, Iran. Int J Infect Dis. 2010;14(1):e28-33. doi: 10.1016/j.ijid.2009.03.002. [PubMed: 19464218].
  • 26. Yu G, Chi X, Wu R, Wang X, Gao X, Kong F, et al. Replication Inhibition of Hepatitis B Virus and Hepatitis C Virus in Co-Infected Patients in Chinese Population. PLoS One. 2015;10(9). e0139015. doi: 10.1371/journal.pone.0139015. [PubMed: 26422607]. [PubMed Central: PMC4589515].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments